Welcome!

News Feed Item

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

NEW YORK, March 18, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Diffuse Large B-Cell Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Diffuse Large B-Cell Lymphoma 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma 37
Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial 37
Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma 37
Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma 38
Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma 39
May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma 40
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
F. Hoffmann-La Roche Ltd. 41
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 41
Celgene Corporation 44
Clinical Trial Overview of Celgene Corporation 44
Amgen Inc. 46
Clinical Trial Overview of Amgen Inc. 46
Novartis AG 48
Clinical Trial Overview of Novartis AG 48
Takeda Pharmaceutical Company Limited 50
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 50
Pharmacyclics, Inc. 51
Clinical Trial Overview of Pharmacyclics, Inc. 51
GlaxoSmithKline plc 52
Clinical Trial Overview of GlaxoSmithKline plc 52
Bayer AG 53
Clinical Trial Overview of Bayer AG 53
AstraZeneca PLC 54
Clinical Trial Overview of AstraZeneca PLC 54
Immunomedics, Inc. 55
Clinical Trial Overview of Immunomedics, Inc. 55
Clinical Trial Overview of Top Institutes / Government 56
National Cancer Institute 56
Clinical Trial Overview of National Cancer Institute 56
Fred Hutchinson Cancer Research Center 61
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 61
Groupe d'Etudes de Lymphomes de L'Adulte 64
Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte 64
Mayo Clinic 65
Clinical Trial Overview of Mayo Clinic 65
The University of Texas M. D. Anderson Cancer Center 66
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 66
FUDAN University 67
Clinical Trial Overview of FUDAN University 67
Memorial Sloan Kettering Cancer Center 68
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 68
The Lymphoma Academic Research Organisation 69
Clinical Trial Overview of The Lymphoma Academic Research Organisation 69
Massachusetts General Hospital 70
Clinical Trial Overview of Massachusetts General Hospital 70
Stanford University 71
Clinical Trial Overview of Stanford University 71
Five Key Clinical Profiles 72
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Disclaimer 166
Source 167

List of Tables

Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 41
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 44
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 46
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 48
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 50
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 51
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 52
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 53
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 54
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014* 55
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 56
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 61
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014* 64
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 65
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 66
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 67
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 68
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014* 69
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 70
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 71

List of Figures
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 165

To order this report: Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
SYS-CON Events announced today that Silicon India has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Published in Silicon Valley, Silicon India magazine is the premiere platform for CIOs to discuss their innovative enterprise solutions and allows IT vendors to learn about new solutions that can help grow their business.
DXWorldEXPO LLC announced today that "IoT Now" was named media sponsor of CloudEXPO | DXWorldEXPO 2018 New York, which will take place on November 11-13, 2018 in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buye...
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, redu...
Jo Peterson is VP of Cloud Services for Clarify360, a boutique sourcing and benchmarking consultancy focused on transforming technology into business advantage. Clarify360 provides custom, end-to-end solutions from a portfolio of more than 170 suppliers globally. As an engineer, Jo sources net new technology footprints, and is an expert at optimizing and benchmarking existing environments focusing on Cloud Enablement and Optimization. She and her team work with clients on Cloud Discovery, Cloud ...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
Nicolas Fierro is CEO of MIMIR Blockchain Solutions. He is a programmer, technologist, and operations dev who has worked with Ethereum and blockchain since 2014. His knowledge in blockchain dates to when he performed dev ops services to the Ethereum Foundation as one the privileged few developers to work with the original core team in Switzerland.
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...